SUMMARY
Immune checkpoint inhibitors (ICI) are an increasingly used form of cancer immunotherapy (IT) with improved overall survival and efficacy compared to conventional chemotherapies in advanced cancers like non-small cell lung carcinoma (NSCLC) and melanoma. However, immune-related adverse events (irAEs) are still common and can be severe. In rare cases, inner ear irAEs have been reported. A pilot prospective longitudinal study was conducted in thirteen patients with melanoma or NSCLC treated with an ICI. A questionnaire based on the Speech, Spatial, and Qualities of Hearing Scale (SSQ), the Health Utilities Index Mark 2 and Mark 3 (HUI2/3), and the So Stoned questionnaire was used in conjunction with audiovestibular testing at baseline, three and six months. Seven out of thirteen patients showed irAEs. Despite inner ear irAE being rare, this study identified one patient with acute bilateral hearing loss within the study group of thirteen patients. Due to the increased use of immunotherapy, it is expected that the number of patients with acute inner ear pathology will rise. In this regard, awareness can lead to prompt diagnosis and treatment, as well as a better understanding of the pathophysiology and incidence of audiovestibular irAE.
(BELG J MED ONCOL 2024;18(3):89–94)
